Patient
SITE001-0092
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE001 (USA) (Dr. Reyes)
consented 2025-12-20
Adverse events
9
Serious AEs
2
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 9
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-11-13 (study day 138); relationship: not assessed
Grade 4 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-10-21 (study day 115); relationship: not assessed; serious criteria: life-threatening
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-09-17 (study day 81); relationship: NOT RELATED
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-09-02 (study day 66); relationship: not assessed
Grade 2 Hypothyroidism — outcome: RECOVERED/RESOLVED; onset 2022-09-02 (study day 66); relationship: RELATED
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-08-24 (study day 57); relationship: not assessed
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-08-02 (study day 35); relationship: not assessed; serious criteria: hospitalization
Grade 1 Neutropenia — outcome: UNKNOWN; onset 2022-07-15 (study day 17); relationship: not assessed
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-07-13 (study day 15); relationship: RELATED
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.